New JNCCN findings shed light on ways to screen people at high risk for pancreatic cancer in PRECEDE study

plymouth conference [April 16, 2024] — New research in the April 2024 issue JNCCN—Journal of the National Comprehensive Cancer Network Demonstrated feasibility of improving early detection and prevention of pancreatic cancer. In recent years, the global incidence of pancreatic cancer has increased sharply, but the overall survival rate is currently only 12%. When pancreatic tumors are detected early and treated with surgical resection, survival rates rise to over 80%, but unfortunately, the vast majority of patients are diagnosed with advanced disease. The Pancreatic Cancer Early Detection (PRECEDE) Alliance is a global effort to improve screening capabilities for this disease. Of the 1,759 participants in the highest-risk cohort, nearly 80% completed baseline imaging through PRECEDE.

“Individuals who are concerned that they are at risk for pancreatic cancer can participate in PRECEDE and obtain an assessment from the PRECEDE website,” explained co-lead author George Zogopoulos, MD, PhD, McGill University Health Center Research Institute and Rosalind and Maurice Goodman Cancer Institute, Canada. “If individuals are assessed to be at increased risk for pancreatic cancer, they will have the opportunity to undergo clinical surveillance for pancreatic cancer based on existing clinical surveillance services in their area. Based on our findings, we recommend that patients with pancreatic cancer be screened based on family history of pancreatic cancer, the presence of potential Oncogene mutations, or both, divide those at high risk for pancreatic cancer into three groups.

Researchers found that people classified into a high-risk subgroup based solely on family history had a higher incidence of pancreatic cysts than people with a known genetic predisposition to pancreatic cancer but no family history.

“The presence of a cyst may identify an increased risk of pancreatic cancer due to changes in the cyst over time, or the presence of a cyst may indicate an inherent aberration of the pancreas that makes it more susceptible to cyst progression or other precancerous growth. individuals,” said the senior author Diane M. Simeone, MD, UC San Diego Moores Cancer Center (NYU Langone Health at the time of study). “Longer follow-up is needed to determine whether familial pancreatic cancer connotes a higher risk of pancreatic cancer compared with pathogenic germline variant (PGV) status in pancreatic cancer susceptibility genes.”

“This study highlights that, despite barriers to widespread implementation of pancreatic cancer screening programs in high-risk populations, multicenter international consortia and longitudinal studies are feasible; the early imaging results of this study suggest the need for further Pancreatic cancer early detection study. Cassady Moravec, Senior Director, Clinical Trials Portfolio and Project Management, Pancreatic Cancer Action Network (PanCAN).

Moravek, patient advocate for NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)^®) The pancreatic cancer team continued: “The poor overall survival rates from pancreatic cancer are often attributed to the fact that most patients have advanced disease at diagnosis, underscoring the need for improved pancreatic cancer screening to detect the disease at its earliest stages. sex. Although the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer recommend screening for pancreatic cancer in specific individuals based on known causative germline variants and family history, this study demonstrates the need for Further research is needed in this area to better tailor surveillance to different subcategories of high-risk individuals. The study also identified a high prevalence of pancreatic cysts in high-risk groups that are genetically based on known pathologies. The risks of change do not exactly overlap. I look forward to building on the infrastructure support of this international consortium to further research in this area to improve access to pancreatic cancer screening for high-risk populations, thereby advancing early detection and prevention of pancreatic cancer. Improve clinical outcomes.

PRECEDE sites are located throughout North America and Europe. Multiple NCCN member institutions are participating, including the University of Pennsylvania Abramson Cancer Center, Dana-Farber Cancer Institute, Fred and Pamela Buffett Cancer Center, Fred Hutchinson Cancer Center, University of Utah Huntsman Cancer Institute, Massachusetts General Hospital Cancer Center, Mayo Clinic Comprehensive Cancer Center, UC San Diego Moores Cancer Center, and Yale Cancer Center/Smilow Cancer Hospital.

To read the entire study, visit JNCCN.org. Free access to “Pancreatic Cancer Early Detection (PRECEDE) Study, a Global Effort to Advance Early Detection: Baseline Imaging Results in High-Risk Individuals” is available until July 10, 2024.

###

about JNCCN—Journal of the National Comprehensive Cancer Network

This book has been read by more than 25,000 oncologists and other cancer care professionals in the United States JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information on innovations in translational medicine and scientific research relevant to oncology health services research, including quality care and value, bioethics, comparative and cost-effectiveness, public policy, and supportive Interventional research and survival in nursing. Jiangxi Nanjing University Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®), review articles detailing guideline recommendations, health services research, and case reports highlighting molecular insights in patient care. Jiangxi Nanjing University Published by Harborside/BroadcastMed. Please visit JNCCN.org.Ask if you are eligible for free subscription Jiangxi Nanjing University, please visit NCCN.org/jnccn/subscribe.follow Jiangxi Nanjing University on twitter @JNCCN.

About the National Comprehensive Cancer Network

National Comprehensive Cancer Network^® (NCCN^®) is a nonprofit alliance of leading cancer centers dedicated to patient care, research and education. NCCN is dedicated to improving and promoting quality, effective, equitable and accessible cancer care so that all patients can live better lives. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) provide transparent, evidence-based expert consensus recommendations for cancer treatment, prevention, and support services; they are the accepted standard for clinical direction and policy in cancer management and are the most comprehensive and frequently updated clinical practice guidelines of any field of medicine.this NCCN Patient Guidelines^® Provide expert cancer treatment information to inform and empower patients and caregivers through support from: NCCN Foundation^®. NCCN also promotes continuing education, global initiatives, policy, and research collaboration and publication in oncology.Please visit NCCN.org to learn more.